Plain-English translation of NCT06061146 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This study is testing whether combining tislelizumab—a newer immunotherapy drug—with standard radiation and chemotherapy works better than standard treatment alone for older adults with advanced esophageal cancer. Researchers want to see if this medication, added to the usual care, helps patients live longer and controls their cancer better while remaining safe.
Standard radiation and chemotherapy has been the main treatment for older patients with advanced esophageal cancer that cannot be surgically removed. This medication has shown promise in treating esophageal cancer on its own, but doctors don't yet know if combining it with standard treatment improves results for older patients.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will be randomly assigned to one of two groups. One group receives the new medication by IV infusion every 3 weeks for one year, combined with radiation and two cycles of chemotherapy pills. The other group receives only the standard radiation and chemotherapy. You will have regular visits to hospitals in China to receive treatment and have blood tests and scans to monitor how well the treatment is working and any side effects you experience.
AI-generated summary from trial data · Jul 6, 2026 · Not medical advice
China